These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21766467)

  • 1. Mechanistic modeling to investigate signaling by oncogenic Ras mutants.
    Stites EC; Ravichandran KS
    Wiley Interdiscip Rev Syst Biol Med; 2012; 4(1):117-27. PubMed ID: 21766467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mathematical investigation of how oncogenic ras mutants promote ras signaling.
    Stites EC; Ravichandran KS
    Methods Mol Biol; 2012; 880():69-85. PubMed ID: 23361982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uncoupling the Oncogenic Engine.
    Schambach A; Schott JW; Morgan MA
    Cancer Res; 2017 Nov; 77(22):6060-6064. PubMed ID: 29097608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of oncogenic RAS on redox balance and implications for cancer development.
    Lim JKM; Leprivier G
    Cell Death Dis; 2019 Dec; 10(12):955. PubMed ID: 31852884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic signaling pathways and deregulated target genes.
    Schäfer R; Schramme A; Tchernitsa OI; Sers C
    Recent Results Cancer Res; 2007; 176():7-24. PubMed ID: 17607912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling.
    Erickson KE; Rukhlenko OS; Posner RG; Hlavacek WS; Kholodenko BN
    Semin Cancer Biol; 2019 Feb; 54():162-173. PubMed ID: 29518522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers.
    Mattox TE; Chen X; Maxuitenko YY; Keeton AB; Piazza GA
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31878223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking oncogenic Ras signaling for cancer therapy.
    Adjei AA
    J Natl Cancer Inst; 2001 Jul; 93(14):1062-74. PubMed ID: 11459867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAS-mediated oncogenic signaling pathways in human malignancies.
    Khan AQ; Kuttikrishnan S; Siveen KS; Prabhu KS; Shanmugakonar M; Al-Naemi HA; Haris M; Dermime S; Uddin S
    Semin Cancer Biol; 2019 Feb; 54():1-13. PubMed ID: 29524560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of the regulatory design on the response of epidermal growth factor receptor-mediated signal transduction towards oncogenic mutations.
    Wolf J; Dronov S; Tobin F; Goryanin I
    FEBS J; 2007 Nov; 274(21):5505-17. PubMed ID: 17916191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors.
    Hafner C; Toll A; Fernández-Casado A; Earl J; Marqués M; Acquadro F; Méndez-Pertuz M; Urioste M; Malats N; Burns JE; Knowles MA; Cigudosa JC; Hartmann A; Vogt T; Landthaler M; Pujol RM; Real FX
    Proc Natl Acad Sci U S A; 2010 Nov; 107(48):20780-5. PubMed ID: 21078999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [RAS mutations at the molecular tumor conference].
    Schäfer R
    Pathologe; 2019 Dec; 40(Suppl 3):355-359. PubMed ID: 31754788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Impact of prenylation inhibition on RAS mutant tumors in preclinical studies].
    Baranyi M; Molnár E; Rittler D; Hegedûs B; Tímár J
    Magy Onkol; 2019 Dec; 63(4):320-329. PubMed ID: 31821387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras.
    Wandler A; Shannon K
    Cold Spring Harb Perspect Med; 2018 Apr; 8(4):. PubMed ID: 28778967
    [No Abstract]   [Full Text] [Related]  

  • 15. Oncogenic Ras Isoforms Signaling Specificity at the Membrane.
    Nussinov R; Tsai CJ; Jang H
    Cancer Res; 2018 Feb; 78(3):593-602. PubMed ID: 29273632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recapitulation of ras oncogene mutations in breast cancer.
    Stamatakos M; Stefanaki C; Kontzoglou K; Masouridi S; Sakorafas G; Safioleas M
    Onkologie; 2010; 33(10):540-4. PubMed ID: 20926903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated K-RAS and its effect on morphological appearance.
    Kiyokawa E; Minato H
    J Biochem; 2014 Sep; 156(3):137-45. PubMed ID: 24958732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic strategies to target RAS-mutant cancers.
    Ryan MB; Corcoran RB
    Nat Rev Clin Oncol; 2018 Nov; 15(11):709-720. PubMed ID: 30275515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling.
    Rukhlenko OS; Khorsand F; Krstic A; Rozanc J; Alexopoulos LG; Rauch N; Erickson KE; Hlavacek WS; Posner RG; Gómez-Coca S; Rosta E; Fitzgibbon C; Matallanas D; Rauch J; Kolch W; Kholodenko BN
    Cell Syst; 2018 Aug; 7(2):161-179.e14. PubMed ID: 30007540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Network analysis of oncogenic Ras activation in cancer.
    Stites EC; Trampont PC; Ma Z; Ravichandran KS
    Science; 2007 Oct; 318(5849):463-7. PubMed ID: 17947584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.